Clinical trials: Irinotecan, completed
Colorectal Neoplasms
A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC
The purpose of this study to assess efficacy and tolerability of combination therapy FOLFOXIRI with Bevacizumab (BV) as a first-line therapy in patients with metastatic colorectal cancer.
- Trial name
- QUATTRO (NCT02246049)
- Testing
- Bevacizumab, 5-fluorouracil, Irinotecan hydrochloride
- Where
- Japan
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- EPS Corporation
Metastatic Colorectal Cancer
Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer
The primary objective of this study is to evaluate the efficacy of Irinotecan in combination with FOLFOX+Bevacizumab versus FOLFOX+Bevacizumab alone in the first-line treatment of patients with metastatic colorectal cancer.
- Trial name
- CHARTA (NCT01321957)
- Testing
- Oxaliplatin, 5FU/LV, Bevacizumab, 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
- Where
- 51 sites in Germany
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Metastatic Colorectal Cancer
Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC
The aim of the trial is to study the efficacy and safety of Cetuximab re-challenge for Chinese Patients with RAS/BRAF wild-type Metastatic Colorectal Cancer.
- Trial name
- NCT04224415
- Testing
- C225+CPT-11
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Yuhong Li